that antigens presented to an immature immune system are tolerogenic 1 . This discovery forms the cornerstone of immunology, as it is the basic tenet of the clonal deletion theory proposed by Burnet 2 , Talmage 3 and Lederberg 4 .
Brestcher and Cohn formulated their two-signal theory in part based on the consideration that this process can be continuous throughout the life-span of animal 5 . For antigens that are present throughout ontogeny, numerous studies have demonstrated the tolerogenic effect of pre-existing antigens on immune competent cells [6] [7] [8] . What was less clear was the fate of self-reactive T cells produced de novo in adults to pre-existing antigens in the periphery, such as cancer antigens. Interestingly, studies with chimera mice suggested that for the same antigen and T cell combination, transgenic T cells specific for allogeneic antigen expressed in the skin were tolerized in neonatal, but not in adult mice 9 .
In recent years bone marrow transplantation has become a promising cancer immunotherapy. Thus T cell tolerance in adult animals to antigens not expressed in the thymus is a fundamental issue considering the implications for immunity generated subsequent to bone marrow transplantation. In addition to a wealth of clinical data showing increased patient survival following bone marrow transplantation, it has also been demonstrated that tumor antigen-specific T cells
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From have been produced after bone marrow transplantation 10 . Likewise, donor cells transplanted into virally-infected baboons generated virus-specific CTL 11 , however it remains unclear whether the antigen-specific T cells were derived from mature T cells in the bone marrow or from T cells produced de novo in the antigen-bearing host.
In order to definitively address whether developing T cells in adult animals remain competent to peripheral tumor antigens, we investigated the development of transgenic T cells specific for tumor antigen P1A in tumor-bearing adult mice and analyzed their immune competence, antigen-induced activation and effector function. Here we report that cancer-specific cells produced de novo in tumorbearing mice survive thymic deletion and remain competent when encountering tumor cells causing the regression of large established tumors.
Materials and methods
Experimental animals and cell lines BALB/c and C57BL/6 mice were purchased from Charles River Labs (Wilmington, MA) under contract with the National Cancer Institute. BALB/c RAG-2(-/-) and BALB/c nude mice were purchased from Taconic (Germantown, NY) and bred in our facility. Mice containing a transgenic T cell receptor for the tumor antigen P1A (P1CTL mice) have been described previously 12 . Mice were housed in a specific-pathogen free environment.
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From Bone marrow transplantation Bone marrow from donor mice was obtained by flushing out marrow from the femur, tibia, and humerus. Red blood cells were lysed with ammonium chloride (Sigma, St. Louis, MO). Mature T cells were depleted by incubation with rat anti-mouse CD4 and CD8 mAbs, followed by goat anti-rat IgG Dynabeads (Dynal, Brown Deer, WI). T cells bound by Dynabeads were removed by magnetic separation, and T cell-depleted bone marrow was injected intravenously. For some treatment groups, T-depleted bone marrow from P1CTL mice was mixed with T-depleted bone marrow from BALB/c mice at a 3:2 ratio before injection.
Nude P1CTL bone marrow transplantation Athymic nude mice were bred with P1CTL mice to obtain F1 mice. F1 mice were screened for the presence of the TCR transgene by staining peripheral blood for the Vα8.3 TCR. F1 mice were bred together to produce F2 mice. Nude pups were screened for the presence or absence of the TCR transgene by PCR of tail DNA. Bone marrow from 3-4 week old TCR transgene-positive or transgene-negative mice was harvested as above. Red blood cells were lysed and bone marrow was injected intravenously.
Tumorigenicity experiments 1-5x10
6 J558 cells were injected subcutaneously in the lower abdomen. In experiments using mixed bone marrow from BALB/c and P1CTL donors, bone marrow was given at days 6 and 13 after tumor challenge. In the Nude P1CTL experiment, bone marrow was given in a single dose on day 2 after tumor challenge. In some experiments, mice were sacrificed Allogeneic skin graft experiments BALB/c mice were anesthetized and a 1-2 cm patch of flank skin was removed and replaced with a similar size patch of C57BL/6 skin. Grafts were bandaged for approximately one week, and mice possessing healthy intact grafts after at least 2 weeks were used for experiments. T-depleted bone marrow (prepared as above) or undepleted spleen cells from BALB/c mice were injected intravenously (bone marrow) or intraperitoneally (spleen cells) in two doses at one week intervals. Mice were observed for signs of graft rejection, and grafts were considered rejected when completely removed from mice.
In vivo cytotoxicity assay Spleen cells from BALB/c mice were pulsed with 10 μg/ml of either P1A (LPYLGWLVF) or a control peptide (YPHFMPTNL) in the presence of either 5 mM or 0.5 mM of CFSE, respectively. After mixing at 1:1 ratio, the labeled cells were injected intravenously into recipients and spleen cells were harvested 4-6 hours later and analyzed by flow cytometry for the relative abundance of the CFSE hi and CFSE low populations. 
Results

Tumor growth did not cause clonal deletion of tumor-specific T cells in the thymus
Since mice with a targeted mutation of RAG-2 lack endogenous T and B cells, tumors can be established in these mice that will not induce adaptive immune response prior to bone marrow transplantation. Taking advantage of this, we began by injecting plasmacytoma J558 into syngeneic RAG-2(-/-) mice.
Once the tumors became palpable, the tumor-bearing mice were reconstituted with a mixture of T cell-depleted bone marrow from both syngeneic wild-type mice and transgenic mice expressing a TCR specific for the unmutated tumor antigen P1A 12 . As a control for the effect of tumor, we also generated chimera mice that were not tumor challenged.
We have previously demonstrated that more than 95% of transgenic T cells express high levels of transgenic TCR 12, 13 , and therefore have the ability to bind to their cognate antigen. Based on this, we used the L d :P1A dimer to identify transgenic T cells 14 . As shown in Fig. 1a 
CD8
-T cells and a decreased proportion of CD4 + CD8 + T cells (Fig. 1a , lower panels). However, the profiles of thymocytes from tumor-free and tumor-bearing mice are indistinguishable (Fig. 1a, b) . Moreover, in contrast to non-transgenic mature T cells, which consist of more CD4 + CD8 -subset, there is a significant skewing toward CD8 + CD4 -subset in both groups. This is consistent with a normal positive selection in both groups.
Since the P1A:L d dimer has relatively low affinity for TCR in comparison with monoclonal antibodies, it is possible that it may not be able to detect P1CTL TCR at lower levels. To overcome this caveat, we also used anti-Vα8.3 TCR
antibody which provides about 10-fold stronger staining of the T cells. As expected, the anti-Vα8.3 TCR antibodies marked T cells with broader levels of TCR/CD3 and thus a higher proportion of T cells. Nevertheless, the relative abundance of each subset was unaltered irrespective of which reagents were used to mark transgenic T cells (Fig. 1a) . Therefore it appears that established tumors in the periphery have little impact on the development of cancer-reactive T cells in the thymus.
Activation of T cells generated de novo in tumor-bearing mice
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From It has been established that self-reactive T cells that exit the thymus are also controlled by peripheral mechanisms, including functional inactivation and activation-induced cell death 6, 15, 16 . We compared the peripheral T cells from tumor-bearing and non-tumor bearing mice for their frequency and phenotype.
As shown in Fig Although we have depleted mature T cells from the bone marrow to barely detectable levels (data not shown), it remains possible that the cells responding to tumor antigens in the periphery are expanded from undepleted mature T cells.
To rule out this possibility, we bred the P1CTL-transgene into the nude (nu/nu) background and used the P1CTL + nu/nu bone marrow cells to reconstitute tumorbearing RAG-2(-/-) hosts. As shown in Fig. 3 , the bone marrow from young P1CTL + nu/nu mice had no transgenic T cells.
Since both donor and recipient mice were incapable of producing mature T cells, all T cells in the chimera mice were produced de novo after bone marrow reconstitution of the tumor-bearing host. One can therefore investigate the responsiveness of the T cells generated in the presence of tumors. In mice that received non-transgenic nu/nu bone marrow, all but one mouse had scarcely
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From detectable levels of P1A-reactive T cells. Expansion of T cells in this mouse can be caused by abnormal up-regulation of P1A antigen, which is expressed at low levels under normal circumstances 12 . However it is interesting to note that a high level of P1A-reactive T cells was found among tumor-infiltrating cells, although considerable variation was observed in different recipients (Fig. 4a ).
These data indicate that even in non-transgenic mice P1A-reactive T cells are generated de novo and preferentially expanded in tumor-bearing hosts.
In order to study the immune competence of P1A-reactive T cells, we The fact that tumor-specific T cells were primed in vivo indicates that they have come into contact with tumor antigens. To determine the functionality of these T cells, we analyzed the tumor-infiltrating T cells from mice that received P1CTL + nu/nu bone marrow cells. As shown in Fig. 4d (top, right) , essentially all P1A-specific T cells exhibit an activated phenotype. Moreover, after P1A peptide stimulation, a high percentage of tumor-infiltrating T cells were capable of producing IFNγ (Fig. 4d, bottom) . Since the TIL remained immune competent in an antigen-rich milieu, contacting pre-existing antigen did not tolerize the newly produced T cells.
To determine whether T cells generated in tumor bearing mice are cytotoxic, we carried out an in vivo cytotoxicity assay comparing the efficiency of elimination of P1A-versus control-peptide pulsed syngeneic T cells. As shown in Fig. 5a , in RAG-2-deficient hosts, the P1A-pulsed and control peptide-pulsed targets are presented at approximately 1:1 ratio. A slight, but statistically insignificant reduction of P1A-pulsed target was observed in one of the naïve WT P1CTL transgenic mice (Fig. 5b) . In the unchallenged recipients of T-depleted P1CTL bone-marrow, the ratio of control to P1A-pulsed targets is approximately 3:1, which is consistent will activation of P1CTL either by homeostatic proliferation or by endogenous P1A antigen. Most remarkably, in tumor bearing mice the ratio has increased to 54:1. These data provide clear evidence that tumor growth activates, rather than silences T cells generated de novo in tumorbearing hosts.
Transplantation of transgenic P1CTL bone marrow provides therapeutic effect to tumor-bearing mice
An important issue is whether tumor-specific T cells generated de novo in tumor-bearing hosts are capable of causing the rejection of tumor cells. As shown in Fig. 6a , with a single dose of bone marrow, we observed a substantial survival advantage and delay in tumor growth in mice receiving P1CTL + nu/nu bone marrow, compared to mice receiving non-transgenic nu/nu bone marrow.
The efficacy of the bone marrow cells is comparable to that of mature T cells, as we and others have reported 14, [17] [18] [19] .
Transplantation of T-depleted bone marrow causes rejection of established allogeneic skin graft
Previous work by Alferink et al. 9 demonstrated that transgenic T cells were neither tolerized nor activated in adult hosts that exclusively expressed Our data also indicated that it is necessary to achieve a high frequency of antigen-specific T cells to reject rapidly growing tumors. Since the technical barrier of genetic reprogramming has been overcome recently 22 , antigen-specific T cells can be produced en masse in tumor-bearing hosts to convey protection against established tumors.
The absence of tumor-induced clonal deletion, as reported here, differs from the clonal deletion in the setting of neonatal tolerance. Thus, previous studies using viral antigen and viral superantigens demonstrated that neonatal tolerance often involves clonal deletion in the thymus 23, 24 . One potential explanation is that the antigens in the peripheral tissues in neonates may be 
